| 查看: 7395 | 回复: 32 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
埃索美拉唑钠 药典标准
|
|||
|
埃索美拉唑钠 有没有药典标准呀 一直没找到... 没有的话，自己生产的话这标准是参考 埃索美拉唑镁 还是 奥美拉唑钠 |
回复此楼» 本帖已获得的红花（最新10朵）
CZX99» 猜你喜欢
农产品中农药监测的免疫传感器的疑问
已经有0人回复
-
纳米传感器监测农药残留的疑惑
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有294人回复
-
谁有人卫版 《毒理学基础》第七版书籍
已经有0人回复
-
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
26考博申请 学or专
已经有15人回复
-
NSCLC脑转移肿瘤模型
已经有0人回复
-
CHP-134这个细胞系哪里有？
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 埃索美拉唑钠原料的开发
已经有16人回复
- 埃索美拉唑钠的重结晶方法
已经有18人回复
- 求助埃索美拉唑钠的研发背景资料
已经有8人回复
- 埃索美拉唑镁肠溶微丸释放时变色
已经有13人回复
- 大家有没有做埃索美拉唑钠项目的进来交流一下！
已经有47人回复
- 【求助】高手请进 关于埃索美拉唑钠盐的紫外图谱
已经有8人回复
- 【求助】埃索美拉唑钠
已经有17人回复
» 抢金币啦！回帖就可以得到:
-
【征稿中！】2026年机械、制造技术与材料国际会议 (MEMTM 2026)
+1/905
-
【IEEE列表会议征稿 】2026年第六届控制理论与应用国际会议（ICoCTA 2026）
+5/870
-
基金高中！
+1/594
-
优质男征女友
+1/469
-
昆明理工大学智能车辆技术团队招聘博士后
+3/222
-
【以色列理工学院全额奖学金硕博士招生】王燕课题组 · 柔性生物界面实验室
+2/118
-
锡基钙钛矿｜超低水氧惰性环境，解锁无铅光伏技术攻关路径
+1/93
-
天平合规性问题
+1/92
-
【半导体薄膜代工】ALD/CVD/磁控溅射/热蒸发全工艺
+1/88
-
南方科技大学刘科院士团队诚聘矿物浮选分离方向研究助理
+1/83
-
大湾区大学刘天辉课题组招收2027级博士生（与中山大学物理学院联合培养）
+1/42
-
大湾区大学刘天辉课题组招收2027级博士生（与中山大学物理学院联合培养）
+1/42
-
山东大学-山东字节信息智能技术实验室2026年招聘博士后
+2/22
-
浙江大学物理高等研究院袁怀洋课题组诚聘博士和博士后
+1/15
-
中国药科大学陈达威课题组招收2027年博士研究生 （药理学）
+1/11
-
南方科技大学环境科学与工程学院陈洪副教授课题组2026年科研助理招聘启事
+1/5
-
联合培养学生招聘-硕博均可
+1/5
-
义翘神州推出全长p-Tau217蛋白，助力阿尔茨海默病下一代生物标志物检测开发
+1/5
-
义翘神州TR-FRET激酶检测试剂盒助力高通量药物筛选
+1/1
-
义翘神州TR-FRET激酶检测试剂盒助力高通量药物筛选
+1/1
5楼2011-08-30 14:55:54
2楼2011-08-30 14:35:50
★
hao8431(金币+1):谢谢参与
hao8431(金币+1):谢谢参与
|
以下是USP34版友原料药镁盐的标准 Esomeprazole Magnesium (es'' oh mep' ra zole mag nee' zee um). C34H36MgN6O6S2·3H2O Trihydrate: 767.17 C34H36MgN6O6S2 Anhydrous: 713.12 1H-Benzimidazole,5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl], magnesium salt (2:1), trihydrate; 5-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole, magnesium salt (2:1), trihydrate [217087-09-7]. DEFINITION Esomeprazole Magnesium contains NLT 98.0% and NMT 102.0% of C34H36MgN6O6S2, calculated on the anhydrous basis. IDENTIFICATION • A. INFRARED ABSORPTION 197K • B. The Sample solution, prepared and tested as directed in the test for Content of Magnesium, exhibits a significant absorption at 285.2 nm. ASSAY • PROCEDURE Solution A: Dissolve 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Solution B: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 100 mL. Mobile phase: Acetonitrile and Solution A (7:13) Standard solution: Transfer 10 mg of USP Omeprazole RS to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of omeprazole. ] Sample solution: Transfer 10 mg of Esomeprazole Magnesium to a 200-mL volumetric flask, and dissolve in about 10 mL of methanol. Add 10 mL of Solution B, and dilute with water to volume. [NOTE—This solution contains 0.05 mg/mL of esomeprazole magnesium. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 1 mL/min Injection size: 20 μL System suitability Sample: Standard solution Suitability requirements Column efficiency: NLT 2000 theoretical plates Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of C34H36MgN6O6S2 in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × (CS/CU) × [Mr1/(2 × Mr2)] × 100 Acceptance criteria: 98.0%–102.0% on the anhydrous basis OTHER COMPONENTS • CONTENT OF MAGNESIUM Lanthanum solution: Transfer 58.7 g of lanthanum oxide into a 1000-mL volumetric flask, wet the substance with some water, and dissolve by cautious addition of 250 mL of hydrochloric acid in 20- to 30-mL portions, cooling between the additions. Add water while stirring, cool to room temperature, and dilute with water to volume. [NOTE—Store the solution in a plastic bottle. ] Standard stock solution: 1000 μg/mL of magnesium in water, from a commercially prepared atomic absorption standard solution. [NOTE—Store the solution in a plastic bottle. ] Standard solution A: Transfer 10.0 mL of Standard stock solution to a 500-mL volumetric flask, add 50 mL of 1 N hydrochloric acid, and dilute with water to volume. Transfer 20.0 rU = = peak response from the Sample solution rS = = peak response from the Standard solution CS = = concentration of omeprazole in the Standard solution (mg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (mg/mL) Mr1 = = molecular weight of esomeprazole magnesium, 713.12 Mr2 = = molecular weight of omeprazole, 345.42 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. [NOTE— This solution contains 2 μg/mL of magnesium. ] Standard solution B: Combine 5.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.1 μg/mL). Standard solution C: Combine 10.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.2 μg/mL). Standard solution D: Combine 15.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.3 μg/mL). Standard solution E: Combine 20.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.4 μg/mL). Standard solution F: Combine 25.0 mL of Standard solution A and 4.0 mL of Lanthanum solution, and dilute with water to 100.0 mL (0.5 μg/mL). [NOTE—Concentrations of the Standard solutions and the Sample solution may be modified to fit the linear or working range of the instrument. When using instruments with a linear calibration graph, the number of Standard solutions can be reduced. ] Blank solution: Transfer 4.0 mL of Lanthanum solution to a 100-mL volumetric flask, and dilute with water to volume. Sample solution: Transfer 250 mg of Esomeprazole Magnesium to a 100-mL volumetric flask, add 20 mL of 1 N hydrochloric acid, swirl until dissolved, and dilute with water to volume. Allow to stand for 30 min. Transfer 10.0 mL of this solution to a 200-mL volumetric flask, and dilute with water to volume. Transfer 10.0 mL of the solution to another 100-mL volumetric flask, add 4.0 mL of Lanthanum solution, and dilute with water to volume. Spectrometric conditions (See Spectrophotometry and Light-Scattering 851 .) Mode: Atomic absorption spectrophotometer Flame: Air–acetylene Analytical wavelength: 285.2 nm Analysis Samples: Standard solution B, Standard solution C, Standard solution D, Standard solution E, Standard solution F, Blank solution, and Sample solution Determine the concentration, Cs, in μg/mL, of magnesium in the Sample solution using the calibration graph. Calculate the percentage of magnesium in the portion of Esomeprazole Magnesium taken: Result = (CS/CU) × (100/(100 F)) × 100 CS = = content of magnesium in the Sample solution as calculated above (μg/mL) CU = = concentration of Esomeprazole Magnesium in the Sample solution (μg/mL) F = = content of water in Esomeprazole Acceptance criteria: 3.30%–3.55%, on anhydrous basis IMPURITIES Organic Impurities • PROCEDURE 1 Solution A: 0.725 g of monobasic sodium phosphate and 4.472 g of anhydrous dibasic sodium phosphate in 300 mL of water, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. If necessary, adjust with phosphoric acid to a pH of 7.6. Mobile phase: Acetonitrile and Solution A (11:29). [NOTE—To improve the resolution, the composition may be changed to 1:3, if necessary. ] System suitability solution: 1 mg of USP Omeprazole RS and 1 mg of USP Omeprazole Related Compound A RS in 25 mL of Mobile phase. [NOTE—Omeprazole Related Compound A is omeprazole sulfone. ] Sample solution: 4 mg of Esomeprazole Magnesium in 25 mL of Mobile phase. [NOTE— Prepare this solution fresh. ] Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 280 nm Column: 4.0-mm × 12.5-cm or a 4.6-mm × 15-cm; 5-μm packing L7. [NOTE— Alternatively, a 3.9-mm × 15-cm column that contains 4-μm packing L1 may be used. ] Flow rate: 0.8–1 mL/min Injection size: 50 μL System suitability Sample: System suitability solution [NOTE—For relative retention times, see Impurity Table 1. ] Suitability requirements Resolution: NLT 3 between omeprazole related compound A and omeprazole Analysis Sample: Sample solution Record the chromatogram for at least 4.5 times the retention time of the omeprazole peak, and measure the peak responses. Identify the impurities based on the retention times shown in Impurity Table 1. Calculate the percentage of any individual impurity in the portion of Esomeprazole Magnesium taken: Result = (rU/rT) × 100 Magnesium, as determined in Specific Tests, Water Determination (%) rU = = peak response for each impurity = = sum of all peak responses Acceptance criteria Individual impurities: See Impurity Table 1. Total impurities: NMT 0.5% Impurity Table 1 • PROCEDURE 2: ENANTIOMERIC PURITY Solution A: Mix 70 mL of 1 M monobasic sodium phosphate with 20 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Dilute 250 mL of this solution with water to 1000 mL. Diluent: Mix 11 mL of 0.25 M tribasic sodium phosphate with 22 mL of 0.5 M dibasic sodium phosphate, and dilute with water to 1000 mL. Mobile phase: Acetonitrile and Solution A (3:17) System suitability solution: 2 mg of USP Omeprazole RS in 10 mL of Diluent. Dilute 1.0 mL of this solution with Diluent to 50 mL. Sample solution: 40 mg of Esomeprazole Magnesium in 5 mL of methanol, and dilute with Diluent to 25 mL. Dilute 1 mL of this solution with Diluent to 50 mL. Chromatographic system (See Chromatography 621 , System Suitability.) Mode: LC Detector: UV 302 nm Column: 4.0-mm × 10-cm; packing L41 Flow rate: 0.6 mL/min Injection size: 20 μL System suitability Sample: System suitability solution Suitability requirements Resolution: NLT 3 between the enantiomer peaks. [NOTE—The elution order is the Renantiomer, followed by the esomeprazole peak, which is the S-enantiomer. ] Analysis rT Name Relative Retention Time Acceptance Criteria, NMT (%) Omeprazole N-oxide a 0.45 0.1 Omeprazole sulfoneb (related compound A) 0.8 0.2 Any other individual impurities — 0.1 Omeprazole 1.0 — a 4-Methoxy-2-[[(RS)-(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-3,5- dimethylpyridine 1-oxide. b 5-Methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1Hbenzimidazole. Sample: Sample solution Calculate the percentage of the R-enantiomer in the portion of Esomeprazole Magnesium taken: Result = (rU/rS) × 100 Acceptance criteria: NMT 0.2% of the R-enantiomer SPECIFIC TESTS • WATER DETERMINATION, Method I 921 : 6.0%–8.0% • COLOR OF SOLUTION Sample solution: 20 mg/mL of Esomeprazole Magnesium in methanol Analysis: Determine the absorbance of this solution at 440 nm, in 1-cm cells, using methanol as the blank. Acceptance criteria: NMT 0.2 ADDITIONAL REQUIREMENTS • PACKAGING AND STORAGE: Preserve in tight containers, protected from light. Store at room temperature. • USP REFERENCE STANDARDS 11 USP Esomeprazole Magnesium RS USP OMEPRAZOLE RS USP OMEPRAZOLE RELATED COMPOUND A RS Omeprazole sulfone, 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]- 1H-benzimidazole. C17H19N3O4S 361.42 [CAS-88546-55-8]. Auxiliary Information— Please check for your question in the FAQs before contacting USP. USP34–NF29 Page 2741 Pharmacopeial Forum: Volume No. 35(3) Page 550 Chromatographic Column— ESOMEPRAZOLE MAGNESIUM rU = = peak response for the R-enantiomer rS = = sum of the peak responses for esomeprazole and R-enantiomer Topic/Question Contact Expert Committee Monograph Elena Gonikberg, Ph.D. Principal Scientific Liaison 1-301-816-8251 (SM32010) Monographs - Small Molecules 3 Reference Standards RS Technical Services 1-301-816-8129 rstech@usp.org Chromatographic columns text is not derived from, and not part of, USP 34 or NF 29 还有EP7.0里面是三水合物的标准，如果需要可以联系我，或留下邮箱我把标准发给你！ |
3楼2011-08-30 14:44:06
4楼2011-08-30 14:50:28
